Key result
Cisplatin rechallenge appears safe in select patients after acute coronary events with proper multidisciplinary evaluation.
Why the study?
Evidence guiding rechallenge with cisplatin after an acute coronary event is limited despite its curative benefit in testicular cancer.
Can cisplatin be safely reintroduced in a patient who experienced a cisplatin-induced acute coronary event?
Case Report (n=1)
Can cisplatin be safely reintroduced in a patient who experienced a cisplatin-induced acute coronary event?
This case demonstrates that with multidisciplinary evaluation and optimized medical management, cisplatin rechallenge can be safely performed after a cisplatin-induced acute coronary event.
Answers are grounded in this paper and cite their sources.
May support multidisciplinary cisplatin rechallenge in select post-MI cases; hypothesis-generating and requires prospective confirmation before practice change.
BACKGROUND: Testicular cancer is the most common malignancy in young men, and cisplatin-based chemotherapy provides excellent long-term survival. However, cisplatin-associated cardiovascular toxicity spans a broad spectrum, and evidence guiding rechallenge after an acute coronary event is limited. CASE SUMMARY: A 24-year-old man with testicular cancer and no cardiovascular risk factors developed chest pain and elevated troponins early in his cisplatin therapy. Coronary angiography revealed a nonocclusive left anterior descending artery thrombus. After treatment with antiplatelet and anticoagulant therapy, the thrombus resolved, and he subsequently underwent a carefully monitored cisplatin rechallenge. DISCUSSION: Given cisplatin's curative benefit, a multidisciplinary team-including cardiology, oncology, and pharmacy-assessed the risks and benefits of continuing therapy. With close surveillance and optimized medical management, including anti-ischemic therapy and anticoagulation, cisplatin was safely reintroduced. TAKE-HOME MESSAGES: Cisplatin-induced myocardial infarction requires prompt recognition and coordinated care. With multidisciplinary evaluation, rechallenge can be safely performed in select patients.
No takes yet. Share an insight, caveat, or question.
Jaffery et al. (2026) conducted a case report in Testicular cancer with cisplatin-induced acute coronary event (n=1). Cisplatin rechallenge was evaluated. Cisplatin rechallenge was safely performed in a 24-year-old man following a cisplatin-induced acute coronary event, supported by multidisciplinary care and optimized medical management.
Synapse has enriched 10 related papers. Consider them for comparative context: